Skip to Main content Skip to Navigation
Journal articles

Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases

Abstract : Objectives: Although nivolumab has shown efficacy against non-small-cell lung cancers (NSCLCs), patients with active brain metastases (BMs) were excluded from pivotal clinical trials. Hence, data regarding nivolumab intracerebral activity and safety in NSCLC patients with BMs are scarce. Materials and methods: We conducted a retrospective multicenter study on NSCLC patients with BMs treated with nivolumab. The primary endpoint was intracerebral objective response rate (IORR), according to RECIST criteria. Secondary endpoints included intracerebral control rate, intracerebral and general progression-free survival (PFS), overall survival (OS) and tolerance. Results and conclusion: Forty-three patients were included. BMs were locally pretreated in 34 (79%) patients and active in 16 (37%) patients. Median follow-up was 5.7 (95% CI: 2.7-8.4) months. IORR and extracerebral response rate were, respectively, 9% (95% CI: 3-23%) and 11% (95% CI: 4-26%). Intracerebral control rate was 51% (95% CI: 37-66%). Median intracerebral and general PFS lasted 3.9 (95% CI: 2.8-11.1) and 2.8 (95% CI: 1.8-4.6) months, respectively. Median OS was 7.5 (95% CI: 5.6-not reached) months. Five neurological adverse events occurred, including 1 grade-4 transient ischemic attack of uncertain imputability and 1 grade-3 neurological deficit; neither required nivolumab discontinuation. Nivolumab intracerebral activity was similar to its reported extracerebral efficacy, with an acceptable safety profile. Prospective and controlled data are needed to determine nivolumab's place in treatment of NSCLC patients with BMs.
Document type :
Journal articles
Complete list of metadata

Cited literature [19 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02940719
Contributor : Michel Salzet Connect in order to contact the contributor
Submitted on : Wednesday, September 16, 2020 - 2:51:57 PM
Last modification on : Wednesday, March 17, 2021 - 2:32:03 PM
Long-term archiving on: : Thursday, December 3, 2020 - 8:22:06 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Citation

Clément Gauvain, Enora Vauléon, Christos Chouaid, Emilie Le Rhun, Laurence Jabot, et al.. Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases. Lung Cancer, Elsevier, 2018, 116, pp.62-66. ⟨10.1016/j.lungcan.2017.12.008⟩. ⟨inserm-02940719⟩

Share

Metrics

Record views

42